Glucosamine and lower mortality and cancer incidence: Selection bias in the observational studies

Glucosamine is a widely used supplement to treat joint pain and osteoarthritis despite inconclusive randomized trial results on its effectiveness. In contrast, observational studies associate glucosamine with significant reductions in mortality and cancer incidence. We evaluated the extent of bias, particularly selection bias, to explain these surprising beneficial effects.

[1]  Dan Liu,et al.  Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: a large prospective cohort study , 2021, British Journal of Nutrition.

[2]  L. Thabane,et al.  Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study , 2021, European Respiratory Journal.

[3]  D. King,et al.  Glucosamine/Chondroitin and Mortality in a US NHANES Cohort , 2020, The Journal of the American Board of Family Medicine.

[4]  S. Suissa,et al.  Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis. , 2020, American journal of epidemiology.

[5]  Raveendhara R. Bannuru,et al.  Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines , 2020, Nature Reviews Rheumatology.

[6]  S. Suissa,et al.  Time‐related biases in pharmacoepidemiology , 2020, Pharmacoepidemiology and drug safety.

[7]  Xianbo Wu,et al.  Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study , 2020, Annals of the Rheumatic Diseases.

[8]  L. Qi,et al.  Glucosamine Use, Inflammation, and Genetic Susceptibility, and Incidence of Type 2 Diabetes: A Prospective Study in UK Biobank , 2020, Diabetes Care.

[9]  J. Reginster,et al.  Glucosamine sulphate: an umbrella review of health outcomes , 2020, Therapeutic advances in musculoskeletal disease.

[10]  Spiros C. Denaxas,et al.  Avoidable flaws in observational analyses: an application to statins and cancer , 2019, Nature Medicine.

[11]  L. Qi,et al.  Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank , 2019, British medical journal.

[12]  S. Schneeweiss,et al.  Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies , 2013, Pharmacoepidemiology.

[13]  M. Egger,et al.  Methods to systematically review and meta-analyse observational studies: a systematic scoping review of recommendations , 2018, BMC Medical Research Methodology.

[14]  M. McCullough,et al.  Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort , 2018, Cancer Causes & Control.

[15]  C. Sudlow,et al.  Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population , 2017, American journal of epidemiology.

[16]  M. Hernán Invited Commentary: Selection Bias Without Colliders. , 2017, American journal of epidemiology.

[17]  S. Suissa,et al.  Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism , 2017, Pharmacoepidemiology and drug safety.

[18]  S. Suissa,et al.  Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores , 2017, Pharmacoepidemiology and drug safety.

[19]  E. Giovannucci,et al.  Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow‐up study , 2016, International journal of cancer.

[20]  Robert Platt,et al.  Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. , 2016, Journal of clinical epidemiology.

[21]  J. Reginster,et al.  Commentary on recent therapeutic guidelines for osteoarthritis. , 2015, Seminars in arthritis and rheumatism.

[22]  S. Schneeweiss,et al.  Practice of Epidemiology Implications of M Bias in Epidemiologic Studies: a Simulation Study , 2022 .

[23]  A. Broom,et al.  Who Uses Glucosamine and Why? A Study of 266,848 Australians Aged 45 Years and Older , 2012, PloS one.

[24]  E. White,et al.  Use of glucosamine and chondroitin in relation to mortality , 2012, European Journal of Epidemiology.

[25]  M. Hernán,et al.  Systematic Reviews and Meta-and Pooled Analyses Bias in Observational Studies of Prevalent Users : Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins , 2012 .

[26]  S. Bae,et al.  Prevalence and factors affecting glucosamine use in Korea: a survey-based study , 2013, Rheumatology International.

[27]  E. White,et al.  Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort , 2011, Cancer Causes & Control.

[28]  Johanna W Lampe,et al.  Specialty Supplements and Prostate Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort , 2011, Nutrition and cancer.

[29]  I. Scheel,et al.  Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. , 2010, JAMA.

[30]  D. Reda,et al.  Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT , 2010, Annals of the rheumatic diseases.

[31]  S. Cole,et al.  Illustrating bias due to conditioning on a collider. , 2010, International journal of epidemiology.

[32]  D. Reda,et al.  The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. , 2008, Arthritis and rheumatism.

[33]  C. Berger,et al.  Prevalence of and factors associated with glucosamine use in Canada. , 2006, Osteoarthritis and cartilage.

[34]  M. Hernán,et al.  The birth weight "paradox" uncovered? , 2006, American journal of epidemiology.

[35]  Michael H Weisman,et al.  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. , 2006, The New England journal of medicine.

[36]  J. Robins,et al.  A Structural Approach to Selection Bias , 2004, Epidemiology.

[37]  S. Greenland Quantifying Biases in Causal Models: Classical Confounding vs Collider-Stratification Bias , 2003, Epidemiology.

[38]  T. Schnitzer,et al.  Recommendations for the Medical Management of Osteoarthrits of the Hip and Knee , 2002 .

[39]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[40]  O. Miettinen,et al.  Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. , 1989, Journal of clinical epidemiology.